RESUMEN
The effects of magnesium supplementation on blood pressure (BP) have been studied for over 25 years and results have been inconsistent. Blood pressure reductions in randomized studies have varied from 12 mmHg reductions to no reduction. The objective of this pilot intervention was to investigate the effect of magnesium supplementation on systolic blood pressure whilst resting and during recovery from aerobic and resistance exercise and on performance. A further objective was to see whether the effect of a high vs low habitual dietary magnesium intake affected these results. Sixteen male volunteers were randomly assigned to either a 300 mg·d(-1) magnesium oxide supplementation (MO) or a control group (CG) for 14 days. Resting blood pressure (BP) and heart rate (HR) were measured before subjects performed a maximal 30 minute cycle, immediately followed by three x 5 second isometric bench press, both at baseline and after the intervention. Blood pressure and heart rate were recorded immediately post exercise and after five minutes recovery. A 3 day food diary was recorded for all subjects to measure dietary magnesium intake. At the end of the intervention, the supplemented group, had a reduction in mean resting systolic BP by 8.9 mmHg (115.125 ± 9.46 mmHg, p = 0.01) and post exercise by 13 mmHg (122.625 ± 9. 88 mmHg, p = 0.01). Recovery BP was 11.9 mmHg lower in the intervention group compared to control (p = 0.006) and HR decreased by 7 beats per minute in the experimental group (69.0 ± 11.6 bpm, p = 0. 02). Performance indicators did not change within and between the groups. Habitual dietary magnesium intake affected both resting and post exercise systolic BP and the subsequent effect of the magnesium supplementation. These results have an implication in a health setting and for health and exercise but not performance. Key pointsMagnesium supplementation will have an effect on resting and recovery systolic blood pressure with aerobic exercise.Magnesium supplementation will have an effect on resting and recovery systolic blood pressure with resistance exercise.Magnesium supplementation did not have an effect on performance indicators.A low habitual dietary magnesium intake will negatively affect blood pressure.A high habitual dietary magnesium intake will impact on the effect of magnesium supplementation.
RESUMEN
G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of dyslipidemia due to its capacity to positively affect serum lipids to a greater extent than other currently marketed drugs. We report a series of tricyclic pyrazole carboxylic acids that are potent and selective agonists of GPR109a. Compound R,R-19a (MK-1903) was advanced through preclinical studies, was well tolerated, and presented no apparent safety concerns. Compound R,R-19a was advanced into a phase 1 clinical trial and produced a robust decrease in plasma free fatty acids. On the basis of these results, R,R-19a was evaluated in a phase 2 study in humans. Because R,R-19a produced only a weak effect on serum lipids as compared with niacin, we conclude that the beneficial effects of niacin are most likely the result of an undefined GPR109a independent pathway.
Asunto(s)
Ácidos Grasos no Esterificados/sangre , Pirazoles/uso terapéutico , Receptores Acoplados a Proteínas G/agonistas , Animales , Humanos , Hipolipemiantes/farmacocinética , Hipolipemiantes/uso terapéutico , Masculino , Niacina/farmacología , Pirazoles/síntesis química , Pirazoles/farmacocinética , Ratas , Receptores Acoplados a Proteínas G/efectos de los fármacos , Receptores Nicotínicos/efectos de los fármacos , Estereoisomerismo , Vasodilatadores/farmacologíaRESUMEN
Tricyclic pyrazole tetrazoles which are potent partial agonists of the high affinity niacin receptor, GPR109a, have been discovered and optimized. One of these compounds has proven to be effective at lowering free fatty acids in vitro and in vivo.
Asunto(s)
Pirazoles/química , Receptores Acoplados a Proteínas G/agonistas , Tetrazoles/química , Vasodilatadores/química , Animales , Perros , Haplorrinos , Humanos , Ratones , Ratas , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismo , Tetrazoles/síntesis química , Tetrazoles/farmacocinética , Vasodilatadores/síntesis química , Vasodilatadores/farmacocinéticaRESUMEN
A series of 5-N,N-disubstituted-5-aminopyrazole-3-carboxylic acids were prepared and found to act as highly potent and selective agonists of the G-Protein Coupled Receptor (GPCR) GPR109b, a low affinity receptor for niacin and some aromatic d-amino acids. Little activity was observed at the highly homologous higher affinity niacin receptor, GPR109a.
Asunto(s)
Ácidos Carboxílicos/síntesis química , Receptores Acoplados a Proteínas G/agonistas , Animales , Aterosclerosis/tratamiento farmacológico , Células CHO , Ácidos Carboxílicos/farmacología , Química Farmacéutica/métodos , Cricetinae , Cricetulus , Diseño de Fármacos , Dislipidemias/tratamiento farmacológico , Humanos , Ligandos , Lipoproteínas HDL/química , Lipoproteínas LDL/química , Modelos Químicos , Niacina/química , Pirazoles/farmacología , Receptores Acoplados a Proteínas G/metabolismo , Receptores NicotínicosRESUMEN
The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (5a, MK-0354), a partial agonist of GPR109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism, but did not induce vasodilation at the maximum feasible dose. Moreover, preadministration of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD2. This profile made 5a a suitable candidate for further study for the treatment of dyslipidemia.
Asunto(s)
Hipolipemiantes/farmacología , Pirazoles/farmacocinética , Receptores Acoplados a Proteínas G/agonistas , Tetrazoles/farmacocinética , Adipocitos/efectos de los fármacos , Animales , Ácidos Grasos no Esterificados/sangre , Humanos , Hipolipemiantes/síntesis química , Hipolipemiantes/uso terapéutico , Lipólisis/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Pirazoles/síntesis química , Receptores Nicotínicos , Tetrazoles/síntesis química , Vasodilatación/efectos de los fármacosRESUMEN
A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series.
Asunto(s)
Benzoatos/química , Ácidos Nicotínicos/química , Receptores Acoplados a Proteínas G/agonistas , Animales , Benzoatos/agonistas , Benzoatos/metabolismo , Células CHO , Cricetinae , Cricetulus , Humanos , Niacina/metabolismo , Ácidos Nicotínicos/agonistas , Ácidos Nicotínicos/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Receptores Acoplados a Proteínas G/fisiología , Receptores Nicotínicos/metabolismo , Receptores Nicotínicos/fisiología , Relación Estructura-ActividadRESUMEN
A series of 5-alkyl pyrazole-3-carboxylic acids were prepared and found to act as potent and selective agonists of the human GPCR, GPR109a, the high affinity nicotinic acid receptor. No activity was observed at the highly homologous low affinity niacin receptor, GPR109b. A further series of 4-fluoro-5-alkyl pyrazole-3-carboxylic acids were shown to display similar potency. One example from the series was shown to have improved properties in vivo compared to niacin.
Asunto(s)
Ácidos/química , Flúor/química , Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacología , Pirazoles/química , Pirazoles/farmacología , Receptores Acoplados a Proteínas G/agonistas , Animales , Ácidos Grasos/metabolismo , Ligandos , Masculino , Ratones , Estructura Molecular , Agonistas Nicotínicos/síntesis química , Pirazoles/síntesis química , Ratas , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismo , Relación Estructura-ActividadRESUMEN
A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization.
Asunto(s)
Ácidos Heterocíclicos/química , Química Farmacéutica/métodos , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/química , Receptores Nicotínicos/química , Adipocitos/metabolismo , Animales , AMP Cíclico/metabolismo , Diseño de Fármacos , Humanos , Cinética , Modelos Químicos , Niacina/química , Pirazoles/química , Ratas , Bazo/metabolismoRESUMEN
Nicotinic acid remains the most effective therapeutic agent for the treatment and prevention of atherosclerosis resulting from low high density lipoprotein cholesterol. The therapeutic actions of nicotinic acid are mediated by GPR109A, a Gi protein-coupled receptor, expressed primarily on adipocytes, Langerhans cells, and macrophage. Unfortunately, a severe, cutaneous flushing side effect limits its use and patient compliance. The mechanism of high density lipoprotein elevation is not clearly established but assumed to be influenced by an inhibition of lipolysis in the adipose. The flushing side effect appears to be mediated by the release of prostaglandin D2 from Langerhans cells in the skin. We hypothesized that the signal transduction pathways mediating the anti-lipolytic and prostaglandin D2/flushing pathways are distinct and that agonists may be identified that are capable of selectively eliciting the therapeutic, anti-lipolytic pathway while avoiding the activation of the parallel flush-inducing pathway. We have identified a number of GPR109A pyrazole agonists that are capable of fully inhibiting lipolysis in vitro and in vivo and not only fail to elicit a flushing response but can antagonize the ability of nicotinic acid to elicit a flush response in vivo. In contrast to flushing agonists, exposure of cells expressing GPR109A to the non-flushing agonists fails to induce internalization of the receptor or to activate ERK 1/2 mitogen-activated protein kinase phosphorylation.
Asunto(s)
Regulación de la Expresión Génica , Agonistas Nicotínicos/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismo , Tejido Adiposo/metabolismo , Animales , Células CHO , Células COS , Chlorocebus aethiops , Cricetinae , Cricetulus , Masculino , Ratones , Ratones Endogámicos C57BL , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Modelos Químicos , Prostaglandina D2/metabolismo , Ratas , Receptores Acoplados a Proteínas G/química , Receptores Nicotínicos/químicaRESUMEN
1-Substituted benzotriazole carboxylic acids have been identified as the first reported examples of selective small-molecule agonists of the human orphan G-protein-coupled receptor GPR109b (HM74), a low-affinity receptor for the HDL-raising drug niacin. No activity was observed at the highly homologous high-affinity niacin receptor GPR109a (HM74A). The high degree of selectivity was attributed to a difference in the amino acid sequence adjacent to a key arginine-ligand interaction allowing somewhat larger ligands to be tolerated by GPR109b.